How it works:
Methoxsalen is a photosensitiser that enhances skin’s response to UVA light. It intercalates with epidermal DNA and, upon UVA exposure, stimulates melanin synthesis and skin repigmentation. It also modulates keratinocyte proliferation in conditions like psoriasis.
Who should consider this:
Patients with widespread vitiligo
Those undergoing systemic PUVA therapy for resistant psoriasis
Individuals requiring enhanced systemic phototherapy (as prescribed)
Cases where topical psoralens are insufficient
Generalised vitiligo
Chronic plaque psoriasis unresponsive to topical treatment
Certain cases of eczema, lichen planus, or cutaneous T-cell lymphoma
Supportive systemic therapy before UVA exposure
Take the tablets orally 1.5 to 2 hours before planned UVA exposure as per dermatologist instructions. The dose is individualised based on weight, phototype, and clinical condition. Avoid sunlight exposure post-dose without protective eyewear and clothing.
Hypersensitivity to methoxsalen or other psoralens
History of skin cancers or photosensitive disorders (e.g., porphyria)
Severe liver dysfunction
Pregnancy and breastfeeding
Use in children only under strict medical supervision
Nausea, dizziness, headache
Increased photosensitivity and sunburn risk
Hyperpigmentation and phototoxic skin reactions
Potential liver enzyme alterations
Eye damage if protective measures are not used during UVA exposure
